What to Know About MBC Treatment-Related Heart Problems
Some MBC treatments can cause or increase the risk of heart problems. Read more about research studying how to monitor and treat cardiotoxicity.
ASCO Experts Update Guidance for Sacituzumab Govitecan (Trodelvy®) for HR+, HER2- MBC
Read for information on the FDA’s expanded approval of Trodelvy® and ASCO’s updated guidance on the use of this drug.
What is Stable Disease and How is it Monitored?
Read about stable disease and current research on monitoring MBC treatment response.
Biomarkers to Guide MBC Treatment Decisions: ESR1, PALB2, TROP2, HRD, ctDNA, and CTCs
In part 3 of a 3-part series, learn about biomarkers that require more research before being recommended to guide treatment decisions.
Biomarkers to Guide MBC Treatment Decisions: dMMR/MSI-H, TMB, and NTRK Fusion
In part 2 of a 3-part series, read about the new recommendations and the dMMR/MSI-H, TMB, and NTRK fusion biomarkers.
Why You Should Consider Repeat Biopsies
Learn about the importance of repeat biopsies and how they affect treatment decisions and clinical trial eligibility.
Biomarkers to Guide MBC Treatment Decisions: PIK3CA, BRCA1/BRCA2, and PD-L1/PD-1
In this part 1 of a 3-part series, read about new recommendations for using biomarkers to make MBC treatment decisions.
Screening for Breast Cancer Brain Metastases
Current guidelines about screening for brain mets are being questioned. Read about the pros and cons of BCBM screening.
Genomic Testing: What Makes Your Tumor Grow?
The U.S. Food and Drug Administration (FDA) has approved two tests to identify genetic alterations in tumors. These tests, which are done on a tumor sample, look for hundreds of known genetic mutations and alterations linked to cancer. The results can potentially be used to make treatment decisions.
Genomic tumor testing is currently not the standard of care for breast cancer patients–but one day it might be. Below you can read about the two tests.
-
-
- National Cancer Institute: FDA Clears Two Genomic Tests
- Practice Update (free registration is required to read the article): Current Concepts in Genomic Profiling for Breast Cancer
- Clinical Cancer Research: Expanded Profiling in MBC
- OncLive: Molecular Profiling Not Yet Standard of Care for MBC
- Metastatic Trial Search: Find Metastatic Breast Cancer Trials with Genomic Testing
-
New Research Presented at San Antonio
The San Antonio Breast Cancer Symposium is a key breast cancer conference that takes place each year. Researchers often use this meeting to report results from large studies that have the potential to change the standard of care for breast cancer treatment.
Below you will find links to some of the findings relevant to women and men living with metastatic breast cancer.
-
- Practice Update:Â Using Circulating Tumor Cells to Choose First-Line Therapy
- Practice Update:Â Alpelisib In Advanced Breast CancerÂ
- SABCS Full Program